This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Talon Therapeutics, Inc. Reports Second Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2012.

"The FDA's decision to approve our NDA seeking accelerated approval of Marqibo (R) (vinCRIStine sulfate LIPOSOME injection) is a seminal event for Talon," stated Steven R. Deitcher, President, Chief Executive Officer and Board Member of Talon Therapeutics. "Our focus now turns to making Marqibo (R) available to patients in the United States. We are operating on parallel commercialization paths, including planning activities to launch Marqibo (R) ourselves, as well as consideration of strategic partnerships."

Recent Corporate Highlights:
  • FDA approves new drug application (NDA) seeking accelerated approval of Marqibo (R) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
  • Enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo (R) in adults (60 years of age and older) with newly diagnosed Ph- ALL.
  • Appointment of Thomas DeZao as Vice President of Commercial Operations and Planning and initiation of commercialization activities.

Three Months Ended June 30, 2012 Financial Results

For the three months ended June 30, 2012, Talon reported a net loss of $60.8 million and deemed dividends attributable to preferred stock of $1.5 million, which when combined, resulted in a net loss applicable to common stockholders of $62.3 million, or $2.85 per share. This compares to a net loss of $6.0 million and deemed dividends of$1.0 million, which when combined, resulted in a net loss of $7.0 million, or $0.33 per share, for the three months ended June 30, 2011. The change in fair value of Talon's preferred stockholders' rights to purchase additional shares of preferred stock contributed to $55.5 million, or $2.54 per share, of the total net loss applicable to common stockholders for the three months ended June 30, 2012. The deemed dividends attributable to preferred stock contributed to $1.5 million, or $0.07 per share, of the total net loss applicable to common stockholders for the three months ended June 30, 2012.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs